OW*P ran from .002 to $3.23 from positive IRB approval and safety data for a medical marijuana cream for psoriasis. Market cap was damn near $500m. Innovation Pharmaceuticals ran from .15 up to $4.93 from positive phase I data with a market cap approaching $1B during that run. And I don't think Oncolix is just going to put out a PR that says phase I had no adverse effects. It's going to note efficacy if there is any, which it should given what we know about the last cohort. This will also be at an escalated dose too, meaning even more efficacy.
News 
Market Data 
Discover 
AI
